Recombinant leukocyte a interferon as single agent therapy or in combination with cimetidine in patients with advanced colo-rectal carcinoma: A phase II investigation

Abstract

Recombinant leukocyte A interferon used as single agent therapy (7.5×106 units/m2 three times weekly intramuscularly) showed very limited clinical efficacy in patients with advanced colo-rectal carcinoma. No objective tumour regressions were documented in 15 evaluable patients, although three patients demonstrated a stable disease status after 12 weeks of treatment. Neither were any objective tumour regressions registered in 13 patients during subsequent combined therapy with Recombinant Leukocyte A Interferon and cimetidine (1000 mg/day orally). Two of the 3 patients maintained their stable disease status. No change in natural killer (NK) cell activity or in antibody dependent cellular cytotoxicity (ADCC) of peripheral blood mononuclear cells was seen during the two treatment periods. ©1985 Informa UK Ltd All rights reserved: reproduction in whole or part not permitted.